Press Release

Morgan Lewis Advises GlaxoSmithKline in Arrowhead Pharmaceuticals License Agreement

Wednesday, November 24, 2021

PRINCETON, November 24, 2021: Morgan Lewis is advising GlaxoSmithKline in an exclusive license agreement with Arrowhead Pharmaceuticals Inc. under which GSK will develop and commercialize ARO-HSD, Arrowhead’s investigational RNA interference (RNAi) therapeutic in a Phase 1/2 trial that is currently being developed as a treatment for patients with nonalcoholic steatohepatitis.

Morgan Lewis partner Amanda Goceljak—along with partners Jennifer Feldsher, Bryan Keighery, and Todd Liao, and associate Mudan He—are representing GSK.

For more, read the announcement.